AU2023239344A1 - Piperazine substituted indazole compounds as inhibitors of parg - Google Patents
Piperazine substituted indazole compounds as inhibitors of parg Download PDFInfo
- Publication number
- AU2023239344A1 AU2023239344A1 AU2023239344A AU2023239344A AU2023239344A1 AU 2023239344 A1 AU2023239344 A1 AU 2023239344A1 AU 2023239344 A AU2023239344 A AU 2023239344A AU 2023239344 A AU2023239344 A AU 2023239344A AU 2023239344 A1 AU2023239344 A1 AU 2023239344A1
- Authority
- AU
- Australia
- Prior art keywords
- formula
- compound
- cancer
- pharmaceutically acceptable
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263322994P | 2022-03-23 | 2022-03-23 | |
| US63/322,994 | 2022-03-23 | ||
| PCT/US2023/064825 WO2023183850A1 (en) | 2022-03-23 | 2023-03-22 | Piperazine substituted indazole compounds as inhibitors of parg |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2023239344A1 true AU2023239344A1 (en) | 2024-10-10 |
Family
ID=86053625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023239344A Pending AU2023239344A1 (en) | 2022-03-23 | 2023-03-22 | Piperazine substituted indazole compounds as inhibitors of parg |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US12269820B2 (https=) |
| EP (1) | EP4496795B1 (https=) |
| JP (1) | JP7783436B2 (https=) |
| KR (1) | KR20240165402A (https=) |
| CN (1) | CN119255994A (https=) |
| AR (1) | AR128846A1 (https=) |
| AU (1) | AU2023239344A1 (https=) |
| CA (1) | CA3245542A1 (https=) |
| CL (1) | CL2024002805A1 (https=) |
| CO (1) | CO2024012798A2 (https=) |
| CR (1) | CR20240391A (https=) |
| DO (1) | DOP2024000187A (https=) |
| IL (1) | IL315722A (https=) |
| MX (1) | MX2024011545A (https=) |
| PE (1) | PE20251690A1 (https=) |
| TW (1) | TW202345809A (https=) |
| WO (1) | WO2023183850A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
| JP2022548690A (ja) * | 2019-09-20 | 2022-11-21 | アイディアヤ バイオサイエンシーズ，インコーポレイティド | Ｐａｒｇ阻害剤としての４－置換インドールおよびインダゾールスルホンアミド誘導体 |
| MX2024011545A (es) | 2022-03-23 | 2024-09-26 | Ideaya Biosciences Inc | Compuestos de indazol sustituidos con piperazina como inhibidores de parg. |
| AU2024253809A1 (en) * | 2023-04-05 | 2025-10-16 | Ideaya Biosciences, Inc. | Combination therapy comprising a parg inhibitor and a topoisomerase inhibitor for treating cancer |
| WO2025046148A1 (en) | 2023-09-01 | 2025-03-06 | Forx Therapeutics Ag | Novel parg inhibitors |
| TW202528308A (zh) * | 2023-09-20 | 2025-07-16 | 美商愛德亞生物科學公司 | Parg抑制劑 |
| WO2025064750A1 (en) * | 2023-09-20 | 2025-03-27 | Ideaya Biosciences, Inc. | Combination therapy with a parg inhibitor |
| CN119859145A (zh) * | 2023-10-20 | 2025-04-22 | 上海璎黎药业有限公司 | 一种杂芳环磺酰胺结构化合物、其药物组合物及应用 |
| WO2025087941A1 (en) | 2023-10-23 | 2025-05-01 | Universite De Geneve | Parg inhibitors in combination with parp inhibitors and uses thereof |
| WO2025087409A1 (zh) * | 2023-10-26 | 2025-05-01 | 上海齐鲁制药研究中心有限公司 | Parg抑制剂 |
| WO2026022150A1 (en) | 2024-07-22 | 2026-01-29 | Forx Therapeutics Ag | Parg inhibitory compounds |
| WO2026026739A1 (zh) * | 2024-07-29 | 2026-02-05 | 海思科医药集团股份有限公司 | 一种磺酰胺化合物及其在医药上的应用 |
| WO2026032385A1 (zh) * | 2024-08-07 | 2026-02-12 | 上海亚虹医药科技有限公司 | 多聚adp核糖水解酶抑制剂及其医药用途 |
| WO2026062066A1 (en) | 2024-09-17 | 2026-03-26 | Forx Therapeutics Ag | Compounds inducing parg degradation |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1157858A (en) | 1979-12-03 | 1983-11-29 | Ikuo Ueda | Quinazoline derivatives |
| DE4407047A1 (de) | 1994-03-03 | 1995-09-07 | Merck Patent Gmbh | Acetamide |
| DE19927415A1 (de) | 1999-06-16 | 2000-12-21 | Bayer Ag | Indolinylharnstoffderivate |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| TW200303304A (en) | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
| US7009052B2 (en) | 2003-03-20 | 2006-03-07 | Warner Lambert Company Llc | Sulfonamide derivatives |
| GB0322722D0 (en) | 2003-09-27 | 2003-10-29 | Glaxo Group Ltd | Compounds |
| TWI332003B (en) | 2004-01-30 | 2010-10-21 | Lilly Co Eli | Kinase inhibitors |
| US20070049593A1 (en) | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| PT1719773E (pt) | 2004-02-24 | 2009-06-03 | Japan Tobacco Inc | Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv |
| EP1735306A2 (en) | 2004-03-25 | 2006-12-27 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
| WO2007014226A2 (en) | 2005-07-26 | 2007-02-01 | The Board Of Trustees Of The University Of Illinois | Compounds for the treatment of neurodegeneration and stroke |
| CA2637933C (en) | 2006-01-24 | 2013-03-12 | Eli Lilly And Company | Indole sulfonamide modulators of progesterone receptors |
| CN101405001A (zh) | 2006-03-20 | 2009-04-08 | 霍夫曼-拉罗奇有限公司 | 抑制btk和syk蛋白质激酶的方法 |
| US20100298289A1 (en) | 2007-10-09 | 2010-11-25 | Ucb Pharma, S.A. | Heterobicyclic compounds as histamine h4-receptor antagonists |
| CN101903025A (zh) | 2007-10-19 | 2010-12-01 | 彼帕科学公司 | 利用苯并吡喃酮-型parp抑制剂治疗癌症的方法和组合物 |
| KR20100122512A (ko) | 2008-07-17 | 2010-11-22 | 아사히 가세이 파마 가부시키가이샤 | 질소 함유 이환성 복소환 화합물 |
| CN101429191B (zh) | 2008-11-03 | 2012-05-23 | 中国药科大学 | 取代的四氢异喹啉衍生物的用途 |
| KR20120114355A (ko) | 2010-01-13 | 2012-10-16 | 글락소스미스클라인 엘엘씨 | 화합물 및 방법 |
| EP2566477B1 (en) | 2010-05-07 | 2015-09-02 | GlaxoSmithKline Intellectual Property Development Limited | Amino-quinolines as kinase inhibitors |
| JP5864546B2 (ja) | 2010-05-07 | 2016-02-17 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | インダゾール |
| US8697739B2 (en) | 2010-07-29 | 2014-04-15 | Novartis Ag | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof |
| JP2013537210A (ja) | 2010-09-16 | 2013-09-30 | ノバルティス アーゲー | １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤 |
| EA026115B1 (ru) | 2010-12-17 | 2017-03-31 | Ф. Хоффманн-Ля Рош Аг | Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение |
| EP2471363A1 (de) | 2010-12-30 | 2012-07-04 | Bayer CropScience AG | Verwendung von Aryl-, Heteroaryl- und Benzylsulfonamidocarbonsäuren, -carbonsäureestern, -carbonsäureamiden und -carbonitrilen oder deren Salze zur Steigerung der Stresstoleranz in Pflanzen |
| JP2014515368A (ja) | 2011-05-26 | 2014-06-30 | 第一三共株式会社 | プロテインキナーゼ阻害剤としての複素環化合物 |
| WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| WO2013067300A1 (en) | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| WO2014026327A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof |
| BR112015015584A2 (pt) | 2012-12-27 | 2017-12-12 | Baruch S Blumberg Inst | novos agentes antivirais contra infecção por hbv |
| US9951027B2 (en) | 2014-02-11 | 2018-04-24 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as MIDH1 inhibitors |
| MX382781B (es) | 2014-04-02 | 2025-03-13 | Intermune Inc | Piridinonas anti-fibroticas. |
| MA41140A (fr) | 2014-12-12 | 2017-10-17 | Cancer Research Tech Ltd | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg |
| MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
| AU2017360939B2 (en) | 2016-11-18 | 2022-03-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 |
| US12491188B2 (en) | 2019-03-29 | 2025-12-09 | Board Of Regents, The University Of Texas System | Small molecule PARG inhibitors and methods of use thereof |
| JP2022548690A (ja) | 2019-09-20 | 2022-11-21 | アイディアヤ バイオサイエンシーズ，インコーポレイティド | Ｐａｒｇ阻害剤としての４－置換インドールおよびインダゾールスルホンアミド誘導体 |
| CA3225500A1 (en) | 2021-10-04 | 2023-04-13 | Ulrich Luecking | Parg inhibitory compounds |
| US20250002491A1 (en) | 2021-10-04 | 2025-01-02 | Forx Therapeutics Ag | N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer |
| EP4479387A1 (en) | 2022-02-14 | 2024-12-25 | ARase Therapeutics Inc. | Inhibitors of parg |
| US20230272485A1 (en) | 2022-02-16 | 2023-08-31 | Boundless Bio, Inc. | Replication stress pathway agent compositions and methods for treating cancer |
| MX2024011545A (es) | 2022-03-23 | 2024-09-26 | Ideaya Biosciences Inc | Compuestos de indazol sustituidos con piperazina como inhibidores de parg. |
| TWI878939B (zh) | 2022-06-29 | 2025-04-01 | 大陸商杭州聖域生物醫藥科技有限公司 | 五元並六元含氮化物、其中間體、製備方法和應用 |
| KR20250073643A (ko) | 2022-10-03 | 2025-05-27 | 포알엑스 테라퓨틱스 아게 | Parg 억제 화합물 |
| EP4646208A1 (en) | 2023-01-06 | 2025-11-12 | Ideaya Biosciences, Inc. | Treatment of er+ breast cancer comprising homologous recombination deficiency using parg inhibitor |
| WO2024173453A1 (en) | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Heteroaryl-substituted imidazopyridine compounds |
| WO2024173514A1 (en) | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Amide and ester-substituted imidazopyridine compounds |
| WO2024173530A1 (en) | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Heteroaryl-substituted pyrazolo/imidazo pyridine compounds |
| WO2024173524A1 (en) | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Heteroaryl-substituted benzimidazole compounds |
-
2023
- 2023-03-22 MX MX2024011545A patent/MX2024011545A/es unknown
- 2023-03-22 TW TW112110751A patent/TW202345809A/zh unknown
- 2023-03-22 WO PCT/US2023/064825 patent/WO2023183850A1/en not_active Ceased
- 2023-03-22 CA CA3245542A patent/CA3245542A1/en active Pending
- 2023-03-22 CR CR20240391A patent/CR20240391A/es unknown
- 2023-03-22 IL IL315722A patent/IL315722A/en unknown
- 2023-03-22 CN CN202380042074.9A patent/CN119255994A/zh active Pending
- 2023-03-22 AR ARP230100697A patent/AR128846A1/es unknown
- 2023-03-22 JP JP2024556141A patent/JP7783436B2/ja active Active
- 2023-03-22 US US18/188,278 patent/US12269820B2/en active Active
- 2023-03-22 AU AU2023239344A patent/AU2023239344A1/en active Pending
- 2023-03-22 EP EP23718143.3A patent/EP4496795B1/en active Active
- 2023-03-22 PE PE2024002037A patent/PE20251690A1/es unknown
- 2023-03-22 KR KR1020247034606A patent/KR20240165402A/ko active Pending
-
2024
- 2024-09-17 CL CL2024002805A patent/CL2024002805A1/es unknown
- 2024-09-20 CO CONC2024/0012798A patent/CO2024012798A2/es unknown
- 2024-09-20 DO DO2024000187A patent/DOP2024000187A/es unknown
-
2025
- 2025-02-28 US US19/066,791 patent/US20250376467A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250376467A1 (en) | 2025-12-11 |
| IL315722A (en) | 2024-11-01 |
| PE20251690A1 (es) | 2025-07-02 |
| CO2024012798A2 (es) | 2024-10-21 |
| AR128846A1 (es) | 2024-06-19 |
| CN119255994A (zh) | 2025-01-03 |
| DOP2024000187A (es) | 2024-12-30 |
| MX2024011545A (es) | 2024-09-26 |
| CR20240391A (es) | 2024-11-05 |
| JP7783436B2 (ja) | 2025-12-09 |
| US20230303556A1 (en) | 2023-09-28 |
| JP2025512780A (ja) | 2025-04-22 |
| KR20240165402A (ko) | 2024-11-22 |
| CA3245542A1 (en) | 2023-09-28 |
| US12269820B2 (en) | 2025-04-08 |
| TW202345809A (zh) | 2023-12-01 |
| WO2023183850A1 (en) | 2023-09-28 |
| EP4496795B1 (en) | 2026-04-01 |
| EP4496795A1 (en) | 2025-01-29 |
| CL2024002805A1 (es) | 2025-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12269820B2 (en) | Piperazine substituted indazole compounds as inhibitors of PARG | |
| US12234244B2 (en) | Substituted piperazines as inhibitors of KRAS G12C | |
| EP3055290B1 (en) | Inhibitors of kras g12c | |
| CN108314677B (zh) | 一种ezh2抑制剂及其用途 | |
| US10144724B2 (en) | Substituted quinazoline compounds and methods of use thereof | |
| US20210030756A1 (en) | Chiral diaryl macrocycles and uses thereof | |
| US11896589B2 (en) | Diazinyl amino acridines and medical uses thereof | |
| WO2025072544A1 (en) | Sulfonamino indazole compounds as inhibitors of parg | |
| EA051714B1 (ru) | Пиперазин-замещенные индазольные соединения как ингибиторы parg | |
| WO2024240877A1 (en) | Pyrazolo-quinolines as selective inhibitors of genotoxic stress-induced ikk/nf- kb pathways for cancer therapy | |
| WO2026068848A1 (en) | N-substituted 9-aminoacridines and their use in the treatment of cancer | |
| HK40027895A (en) | Inhibitors of kras g12c | |
| HK1227862B (en) | Inhibitors of kras g12c | |
| HK1227862A1 (en) | Inhibitors of kras g12c | |
| NZ719076B2 (en) | Inhibitors of kras g12c |